This company listing is no longer active
Tryp Therapeutics (TRYP) Stock Overview
A clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
TRYP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Tryp Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.06 |
| 52 Week High | CA$0.11 |
| 52 Week Low | CA$0.01 |
| Beta | -1.28 |
| 1 Month Change | 140.00% |
| 3 Month Change | 50.00% |
| 1 Year Change | -25.00% |
| 3 Year Change | -92.77% |
| 5 Year Change | n/a |
| Change since IPO | -91.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| TRYP | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -7.7% | 2.1% | -0.1% |
| 1Y | -25.0% | 1.7% | 23.9% |
Return vs Industry: TRYP underperformed the Canadian Pharmaceuticals industry which returned 64.2% over the past year.
Return vs Market: TRYP underperformed the Canadian Market which returned 5.3% over the past year.
Price Volatility
| TRYP volatility | |
|---|---|
| TRYP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in CA Market | 16.3% |
| 10% least volatile stocks in CA Market | 3.7% |
Stable Share Price: TRYP's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine TRYP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Jason Carroll | entropyneurodynamics.com |
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company’s program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications.
Tryp Therapeutics Inc. Fundamentals Summary
| TRYP fundamental statistics | |
|---|---|
| Market cap | CA$5.79m |
| Earnings (TTM) | -CA$2.95m |
| Revenue (TTM) | n/a |
Is TRYP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRYP income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.95m |
| Earnings | -CA$2.95m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.031 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -90.5% |
How did TRYP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/02 16:50 |
| End of Day Share Price | 2024/05/02 00:00 |
| Earnings | 2024/02/29 |
| Annual Earnings | 2023/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Entropy Neurodynamics Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Higgins | Ladenburg Thalmann & Company |